IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American: IGC) commented on recent federal momentum toward possible Schedule III reclassification for cannabinoids and positioned itself as a focused beneficiary within the FDA-regulated pharmaceutical pathway. The company highlighted its lead candidate, IGC-AD1, currently in a Phase 2 CALMA study for agitation associated with Alzheimer’s disease, and emphasized a long‑horizon strategy built on microdosing, safety, patents, and AI-driven drug development.

IGC outlined potential long-term benefits if policy evolves, including expanded clinical institution participation, more efficient pharma-grade manufacturing and supply chains, and improved engagement from financial institutions and capital markets.

IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued an updated coverage report on December 10, 2025, following IGC's Q2 results. Ascendiant raised its price target to $4.75 and said more positive clinical data and program progress in 2025/26 could act as catalysts for the stock.

The company clarified that analyst reports reflect the analysts' views, that IGC is not responsible for analysts' content or timelines, and provided a link to obtain the full Ascendiant report.

IGC Pharma (NYSE:IGC) announced it has reached 65% patient enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease as of December 9, 2025. The company said enrollment has accelerated and remains on track for trial completion in early 2026. The release notes a hybrid recruitment approach: 25% of participants were recruited via targeted social-media campaigns and 75% via clinical sites. Interim analyses previously reported by the company showed clinical and statistically significant reductions in agitation. IGC continues to expand U.S. and Canada clinical operations and to focus on data quality and site performance.

IGC Pharma (NYSE:IGC) announced publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences" on December 2, 2025, a caregiver-focused book sponsored by IGC and authored by clinical neuropsychologists including Dr. Juan Carlos Arango-Lasprilla and Dr. Sandra Báez.

The book combines science-based educational chapters (disease progression, diagnosis, treatments, caregiver health, planning) with first-person caregiver stories addressing emotional, behavioral, and social challenges. IGC said the publication aligns with its mission while it advances IGC-AD1 in the Phase 2 CALMA trial for agitation in Alzheimer's dementia and develops AI-driven therapeutic programs.

IGC Pharma (NYSE American: IGC) announced advances in MINT-AD, a Multimodal Interpretable Transformer for Alzheimer’s that uses AI and global longitudinal datasets to identify socioeconomic risk factors tied to cognitive decline. The model was trained on 14 large-scale HRS-based studies spanning the USA, Africa, Mexico, China, Costa Rica, Puerto Rico, Chile, Brazil, England, Thailand, Indonesia, India, and Korea. The initiative targets risk stratification, early detection, and simulation of disease progression under interventions, and complements ongoing IGC-AD1 clinical trials aimed at agitation and potential disease-modifying therapies.

IGC says the work may enable earlier prediction, personalized non-pharmacological interventions, and data-driven public health strategies.

IGC Pharma (NYSE American: IGC) reported Q2 FY2026 results for the quarter ended September 30, 2025, and outlined operational progress.

Key items: Phase 2 CALMA enrollment surpassed 50%; a strategic divestiture of a Vancouver manufacturing facility closed for $2.7 million producing an approximate $1.1 million non-cash profit and eliminating $600,000 in annual expenses; other net income rose 2,407%; R&D spending increased 73% to $1.6 million; revenue declined ~54% to $191,000; net loss was $1.8 million ($0.02/share). The company noted NIA recognition for its AI work and ongoing pipeline advances including IGC-M3 and patent allowance for IGC510.

IGC Pharma (NYSE:IGC) announced that the USPTO granted U.S. Patent No. 12,465,589 on November 11, 2025 for "Methods and Composition for Treating CNS Disorders."

The patent covers the proprietary formulation used in IGC-AD1, the company's lead candidate now in the Phase 2 CALMA trial for agitation in Alzheimer's disease, and claims effects on amyloid-beta, tau phosphorylation, mitochondrial function, and behavioral symptoms including agitation, memory, cognition, anxiety, and sleep disturbances.

IGC Pharma (NYSE American: IGC) will host a mid-year fiscal 2026 shareholder update call on Monday, November 17, 2025 at 11:00 a.m. ET to review operational progress for the quarter and mid-year ended September 30, 2025.

Participants may join by phone using access code 146922 or via live webcast at the provided URL; a replay will be available until February 12, 2026.

IGC Pharma (NYSE:IGC) announced an expansion of its AI-powered in-silico drug discovery platform on November 3, 2025, adding retrosynthetic analysis, molecular docking, toxicology/genotoxic assessment, and predictive bioactivity modeling.

The upgrade aims to accelerate identification and optimization of Alzheimer's candidates by prioritizing compounds in its patent portfolio, predicting target interactions, and flagging toxicity earlier to reduce experimental burden. Ongoing programs noted include IGC-AD1 (Phase 2), TGR-63 (preclinical plaque clearance in cortex and hippocampus), IGC-1C (tau/GLP-1 dual action), and IGC-1A (AI-identified GLP-1 agonist).